Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Testing Part B Payment Cuts: Sequester Means Providers Get ASP+4%

This article was originally published in RPM Report

Executive Summary

Cutting the payment level for Medicare Part B drugs is a perennial budget proposal, but never gets very far in Congress. Now, thanks to the sequester, Part B payments have been cut from ASP+6% to ASP+4.3%. Will it stick?

You may also be interested in...

Oncologists Move Against Medicare Part B Drug Payment, Pricing ‘Attacks’

Remember what happened the last time physician groups opposed federal efforts to curtail Medicare spending on Part B drugs?

Cancer Drug Access Unaffected By Medicare Sequester, CMS’ Blum Says

Fears that sequestration cuts to Medicare Part B drug payments would lead to drug access issues have failed to materialize, CMS’ Jonathan Blum tells the FDA/CMS Summit.

Medicare Rx and the Sequester Impact: Making Headlines, But is There a Commercial Impact?

Two large pharmaceutical manufacturers weigh in on whether the sequester is impacting their injectables business. The answer so far: not really. The same story goes for the sequester and Part D, though Lilly is seeing higher than expected Part D discounts in 2013.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts